Determination of neutralizing titers of polyclonal Ig purified from sera of infected individuals and of neutralizing monoclonal IgG using HIV-1Bx08
. | Neutralizing titer, μg/mL . | . | |
|---|---|---|---|
. | iMDDCs, purified at 99% . | PHA-stimulated PBMCs . | |
| Polyclonal IgG | |||
| IgG no. 8 | 35 | 170 | |
| IgG no. 44 | 55 | 265 | |
| IgG no. 24 | 60 | 390 | |
| IgG no. 11 | 165 | — | |
| IgG no. 2 | 240 | — | |
| IgG no. 3 | 275 | — | |
| IgG control | — | — | |
| Polyclonal IgA | |||
| IgA no. 8 | 210 | 190 | |
| IgA no. 6 | ND | 220 | |
| IgA no. 35 | — | ND | |
| IgA control | — | — | |
| Monoclonal IgG | |||
| 2F5 IgG1 | 2 | 40 | |
| 447-52D IgG3 | 5 | 50 | |
| IgG1 b12 | 2 | 50 | |
| 2G12 IgG1 | 2 | > 50 | |
| 4E10 IgG1 | 3 | > 50 | |
. | Neutralizing titer, μg/mL . | . | |
|---|---|---|---|
. | iMDDCs, purified at 99% . | PHA-stimulated PBMCs . | |
| Polyclonal IgG | |||
| IgG no. 8 | 35 | 170 | |
| IgG no. 44 | 55 | 265 | |
| IgG no. 24 | 60 | 390 | |
| IgG no. 11 | 165 | — | |
| IgG no. 2 | 240 | — | |
| IgG no. 3 | 275 | — | |
| IgG control | — | — | |
| Polyclonal IgA | |||
| IgA no. 8 | 210 | 190 | |
| IgA no. 6 | ND | 220 | |
| IgA no. 35 | — | ND | |
| IgA control | — | — | |
| Monoclonal IgG | |||
| 2F5 IgG1 | 2 | 40 | |
| 447-52D IgG3 | 5 | 50 | |
| IgG1 b12 | 2 | 50 | |
| 2G12 IgG1 | 2 | > 50 | |
| 4E10 IgG1 | 3 | > 50 | |
Purified HIV-1Bx08 was preincubated with serial concentrations of polyclonal Ig purified from sera of HIV-1 patients or of neutralizing monoclonal IgG.
Abbreviations are explained in Table 1.